Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul-Sep;5(3):155-61.
doi: 10.4103/2279-042X.185709.

Pharmaceutical laws and regulations in Iran: An overview

Pardis Zaboli  1 , Amir Hashemi-Meshkini  2 , Mehdi Varmaghani  2 , Hadi Gholami  3 , Iman Vazirian  3 , Hedieh-Sadat Zekri  4 , Shahriar Eslamitabar  3 , Abbas Kebriaeezadeh  5
Affiliations
Review

Pharmaceutical laws and regulations in Iran: An overview

Pardis Zaboli et al. J Res Pharm Pract. 2016 Jul-Sep.

Abstract

The pharmaceutical legal framework is a very important infrastructure in achieving predefined goals in pharmaceutical sector: Accessibility, quality, and rational use of medicine. This study aims to review the current pharmaceutical sector-related legal provisions in Iran where the Food and Drug Organization (FDO) is in charge of regulating all issues related to the pharmaceutical sector. The main laws and regulations enacted by parliament and cabinet and even internal regulations enacted by the Ministry of Health or Iran FDO are reviewed. Different laws and regulations are categorized according to the main goals of Iran national drug policy.

Keywords: Accessibility; availability; counterfeit medicines; pharmaceutical trade-related aspects; rational use of medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The structure of pharmaceutical legislative system in Iran
See this image and copyright information in PMC

References

    1. Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med. 2008;5:e22. - PMC - PubMed
    1. Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, et al. Drugs for neglected diseases: A failure of the market and a public health failure? Trop Med Int Health. 2001;6:945–51. - PubMed
    1. Martin S, Scott JT. The nature of innovation market failure and the design of public support for private innovation. Res Policy. 2000;29:437–47.
    1. World Health Organization. How to Design and Implement a National Drug Policy. 2nd ed. Geneva: World Health Organization; 2001.
    1. Lotfi K. Iran's drug industry in the past 80 years (Part 1) Chem Dev. 2000;4:6–11.